The present invention relates to the asymmetric synthesis of substituted dihydrobenzofiirans.
BACKGROUND OF THE INVENTION
Schizophrenia affects approximately 5 million people. The most prevalent treatments for schizophrenia are currently the 'atypical' antipsychotics, which combine dopamine (Da) and serotonin (5-HTzA) receptor antagonism. Despite the reported improvements in efficacy and side-effect liability of atypical antipsychotics relative to typical antipsychotics, these compounds do not appear to adequately treat all the symptoms of schizophrenia and are accompanied by problematic side effects, such as weight gain (Allison, D. B., et. al., Am. J. Psychiatry, 156: 1686-1696, 1999; Masand, P. S., Exp. Opin. Phartnacother. I: 377-389,2000; Whitaker, R., Spectrum Life Sciences. Decision Resources. 2:1-9,2000).
Atypical antipsychotics also bind with high affinity to 5-HTzc receptors and function as 5-HTzc receptor antagonists or inverse agonists. Weight gain is a problematic side effect associated with atypical antipsychotics such as clozapine and olanzapine, and it has been suggested that 5-HTac antagonism is responsible for the increased weight gain. Conversely, stimulation of the S-HT2c receptor is known to result in decreased food intake and body weight (Walsh et. al, Psychopharrriacology 124: 57-73,1996; Co wen, P. J., et. al., Human Psychopharroacology 10: 385-391, 1995; Rosenzweig-Lipson, S., et. al., ASPET abstract, 2000).
Several lines of evidence support 4 role for 5-HTjc receptor agonism or partial agonism as. a treatment for schizophrenia. Studies suggest that 5-HTzc antagonists increase
• *
synaptic levels of dopamine and may be effective in animal models of Parkinson's disease (Di Matteo, V., et. al., Neuropharmacology 37: 265-272, 1998; Fox, S. R, et. al, Experimental Neurology 151: 35-49,1998). Since the positive symptoms of schizophrenia are associated with increased levels of dopamine, compounds with actions

opposite to those of 5-HTjc antagonists, such as S-HTc agonists and partial agonists, ilould reduce levels of synaptic dopamine. Recent studies have demonstrated that 5-HT2c agonists decrease levels of dopamine in the prefrontal cortex and nucleus accumbens (Millan, M. J., et. al., Neuropharmacology 37: 953-955,1998; Di Matteo, V., et. al., Neuropharmacology 38: 1195-1205, 1999; Di Giovanni, G., et. al., Synapse 35: 53-61, 2000), brain regions that are thought to mediate critical antipsychotic effects of drugs like clozapine. However, S-HTic agonists do not decrease dopamine levels in the striatum, the brain region most closely associated with extrapyramidal side effects. In addition, a recent study demonstrates that 5-HTic agonists decrease firing in the ventral tegmental area (VTA), but not in the substantia nigra. The differentia] effects of 5-HTac agonists in the mesoHmbic pathway relative to the nigrostriatal pathway suggest that 5-HT2C agonists have limbic selectivity, and will be less likely to produce extrapyramidal side effects associated with typical antipsychotics.
SUMMARY OF THE INVENTION
As described herein, the present invention provides methods for preparing compounds having activity as SHTzc agonists or partial agonists. These compounds are useful for treating disorders including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, substance-induced psychotic disorder, L-DOPA-induced psychosis, psychosis associated with Alzheimer's dementia, psychosis associated with Parkinson's disease, psychosis associated with Lewy body disease, dementia, memory deficit, intellectual deficit associated with Alzheimer's disease, bipolar disorders, depressive disorders, mood episodes, anxiety disorders, adjustment disorders, eating disorders, epilepsy, sleep disorders, migraines, sexual dysfunction, gastrointestinal disorders, obesity, or a central nervous system deficiency associated with trauma, stroke, or spinal cord injury. Such compounds include those of formula II:
(Figure Removed) or a pharmaceutically acceptable salt thereof, wherein each of Rla, R2a, R3a, AT, q, and y is as defined herein.
The present invention also provides synthetic intermediates useful for preparing such compounds.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
The methods and intermediates of the present invention are useful for preparing compounds as described in, e.g. U.S. patent application entitled "Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same," filed in the name of Jonathan Gross, et al., having serial number 11/113,170, filed April 22,2005, and claiming benefit to US application 10/970,014, filed October 21,2004, and US provisional application 60/514,454, filed on October 24,2003, each of which is hereby incorporated herein by reference in its entirety for all purposes. US application 10/970,014, filed October 21, 2004 is published as US 2005/0143452 Al. It teaches that conversion of the tosylate (7) to the amine (1) can be accomplished, for example, by treatment with sodium azide in a solvent such as dimethylsulfoxide followed by reduction of the azide or direct treatment with an appropriately substituted amine to provide the compounds of Formula 1. Additionally, longer alkyl chains (i.e. 2-aminoethyl) may be prepared, for example, via treatment of (7) with sodium cyanide in a solvent such as dimethylsulfoxide followed by reduction of the nitrile.

(Figure Removed) Proc. A: 1. a) NaN3, DMSO and b) reduction, or 2. NHRR'/DMSO Proc. B: 1. a) NaCN/DMSO and b) Hj/5% Rh on AI203, NH4OH In certain embodiments, the present compounds are generally prepared according to Scheme I set forth below:
(Figure Removed) In Scheme I above, each of R1, R2, Ry, Ar, Y, R8, X, X1, q, and m is as defined below and in classes and subclasses as described herein.
It will be appreciated that although Scheme I depicts a method for preparing a specific enantiomer of formula I, the opposite enantiomer is similarly prepared using the appropriate glycidyl ether.

In one aspect, the present invention provides methods for preparing a chiral non-racemic biaryl compound of formula D according to the steps depicted in Scheme I, above. Catalyst and reaction conditions for the Suzuki reaction of step S-1 above are well known in the art. See, for example, Miyaura, R; Suzuki, A. Chem. Rev. 1995,95,2457. In certain embodiments, the Suzuki coupling at step S-1 is performed in the presence of a palladium containing compound. In other embodiments, the palladium containing compound is Pd(PPhj)4. The reaction may also be performed in the presence of a base. In certain embodiments, the base is MOH, MaCOs, or MjPO*, wherein each M is independently an alkali metal. In some embodiments, the alkali metal is sodium, potassium, or lithium. In other embodiments, step S-1 is performed in the presence of NaOH. The reaction is optionally carried out in the presence of a solvent. Suitable solvents for the coupling at step S-1 include dimethoxyethane, toluene, ethanol,

isopropanol, methanoJ, and tetrahydrofuran (THF). In certain embodiments, the suitable Solvent for the coupling step of S-l includes water. In certain embodiments, the Suzuki coupling reaction is carried out at a temperature in the range of about 20 °C to about the temperature sufficient to reflux the solvent or mixture thereof. In other embodiments, the coupling reaction is carried out at about 60 °C to about 90 °C. In still other embodiments, the coupling reaction is carried out at about 70 °C to about 80 °C.
As depicted in Scheme I above, a compound of formula B is haJogenated at step S-2 to form a compound of formula C wherein X is halogen. One of ordinary skill in the art would recognize that a variety of halogenating agents are suitable for preparing a compound of formula C from a compound of formula B. In certain embodiments, X is bromo and the halogenating agent used at step S-2 is bromine. In other embodiments, X is bromo and the halogenating agent used at step S-2 is a compound containing an N-Br group (e.g., N-bromosuccinimide). Other brominating agents are known to those skilled in the art. In certain embodiments, one or more additives are used in the halogenation reaction. These additives include inorganic acid such as H2S04 (used, for example, with an N-Br brominating agent), Lewis acid, or AcONa (used, for example, with bromine). In other embodiments, the halogenation at step S-2 is performed in a suitable solvent. Suitable solvents for the halogenation at step S-2 include protic solvents, ethers, chlorinated hydrocarbons, and mixtures thereof. Such suitable solvents include dioxane, THF, acetic acid, CHjCb, CHC13, CC14, dichloroethane, and the like. In some embodiments, the reaction is performed at a temperature of about 18 °C to about the temperature sufficient to reflux the solvent. In other embodiments, the additive is p-toluenesulfonic acid and the solvent is acetic acid or formic acid.
At step S-3, the halogenated compound of formula C is treated with a suitable Grignard reagent or magnesium metal then a chiral non-racemic epoxide of the formula:
wherein L is a suitable leaving group. In other embodiments, said reagent is of formula RMgX2, wherein X2 is halogen and R is an alkyl group.
As defined above, L is a suitable leaving group. Suitable leaving groups are well known in the art, e.g., see, "Advanced Organic Chemistry," Jerry March, 5th Ed., pp. 445-44g, John Wiley and Sons, N.Y. Such leaving groups include, but are not limited to, halogen, alkoxy, sulfonyloxy, optionally substituted alkylsulfonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy. Examples of

suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyloxy %nesyloxy), tosyloxy, triflyloxy, nitrophenylsulfonyloxy (nosyloxy), and bromophenylsulfonyloxy (brosyloxy). In certain embodiments, L is halogen. In other embodiments, L is an optionally substituted alkylsulfonyloxy, optionally substituted alkenylsulfonyloxy, or optionally substituted arylsulfonyloxy group.
At step S-4, a compound of formula D or D' or a mixture of the two is treated with a suitable reagent to form a compound of formula E. In certain embodiments, a compound of formula D and/or D' is treated with a reagent containing a suitably protected ammo group to form a compound of formula E wherein R2 is a protected amino group. In other embodiments, a compound of formula D and/or D' is treated with a suitable cyano reagent to form a compound of formula E wherein R2 is CN. In some embodiments treatment is carried out to form the compound having formula E where R2 is NS.
The hydroxyl group of formula E is converted to an ORy moiety at step S-5 to form a compound of formula F. In certain embodiments, said ORy moiety is a suitable leaving group as described herein. In particular, Ry may be an organosulfonyl group. At S-6 the compound having formula F is cyclized to form the compound I, where necessary with the use of conditions for cleaving the protecting group R1. Step S-7 includes reduction of an azide or nitrile as explained above or converting a protected amino group as R2 into an amino group.
Unless otherwise indicated, the following terms have the following meanings:
The term "alkyl," as used herein, refers to a hydrocarbon group having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, and more preferably 1 to 4 carbon atoms. The term "alkyl" includes, but is not limited to, straight and branched groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl. The term "lower alkyl" refers to an alkyl group having 1 to 4 carbon atoms.
The term "alkenyl," as used herein refers to a straight or branched hydrocarbon group having 2 to 8 carbon atoms and that contains 1 to 3 double bonds. Examples of alkenyl groups include vinyl, prop-1-enyl, allyl, methallyl, but-1-enyl, but-2-enyl, but-3-enyl, or 3,3-dimethylbut-l-enyl. The term "lower alkenyl" refers to a straight or branched alkenyl group having 1 to 4 carbon atoms.
The term "cycloaliphatic," as used herein, refers to a saturated or partially unsarurated hydrocarbon monocyclic or bicyclic ring having 3 to 10 carbon atoms and

more preferably 5 to 7 carbon atoms. In certain embodiments, the cyclic cycloaliphatic <|koup is bridged. As used herein, the term "bridged" refers to a cycloaliphatic group that contains at least one carbon-carbon bond between two non-adjacent carbon atoms of the cycloalkyl ring. As used herein, the term "partially unsaturated" refers to a nonaromatic cycloaliphatic group containing at least one double bond and, in certain embodiments, only one double bond. In certain embodiments, the cycloaliphatic group is saturated. The cycloaliphatic group may be unsubstituted or substituted as described hereinafter.
The term "alkylcycloaliphatic," as used herein, refers to the group -(CH2)rCycloaliphatic, where cycloaliphatic is as defined above and r is 1 to 6, preferably 1 to 4, and more preferably 1 to 3.
The term "heterocycloalkyl," as used herein, refers to a 3 to 10 membered monocycJic or bicyclic ring having 1 -3 heteroatoms independently selected from oxygen, nitrogen, or sulfur. In certain embodiments, heterocycloalkyl refers to a 5 to 7 membered ring having 1 -2 heteroatoms independently selected from oxygen, nitrogen, or sulfur. The heterocycloalkyl group may be saturated or partially unsaturated, and may be monocyclic or bicyclic (such as bridged). Preferably, the heterocycloalkyl is monocyclic. The heterocycloalkyl group may be unsubstituted or substituted as described hereinafter.
The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic, bicyclic and tricyclic ring systems having a total of six to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring". The term "aryloxy," as used herein, refers to the group -OAr, where Ar is a 6-10 membered aryl group. The term "aralkoxy", as used herein, refers to a group of the formula -0(CH2)rAr, wherein r is 1 -6. The term "aryloxyalkyl", as used herein, refers to a group of the formula -(CH2)rOAr, wherein r is 1-6.
The term "heteroaryl", used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each ring in the system contains 3 to 7 ring members. The term 'fheteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic". In certain embodiments,

such heteroaryl ring systems include fiiranyl, thienyl, pyrazolyl, imidazolyl, isoxazolyl,
&
oxadiazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidyl, pyridazinyl, triazinyl, thiazolyl,
triazolyl, tetrazolyl, quinolinyl, isoquinolinyl, quinazolinyl, indolinyl, indazolyl, benzothienyl, benzofluranyl, benzisoxazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, isoindolyl, and acridinyl, to name but a few.
The term "heteroaralkyl", as used herein, refers to a group of the formula -(CHa^Het, wherein Het is a heteroaryl group as defined above and r is 1-6. The term "heteroarylalkoxy", as used herein, refers to a group of the formula -O(CH2)rHet wherein Het is a heteroaryl group as defined above and r is 1-6. Any aryl, heteroaryl, cycloaliphatic or heterocycloalkyl may optionally be substituted with 1 to 5 substituents independently selected from halogen, hydroxyl, cyano, alkyl of 1 to 6 carbon atoms, perfluoroalkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or perfluoroalkoxy of 1 to 6 carbon atoms.
The term "perfluoroalkyl," as used herein, refers to an alkyl group as defined herein in which all hydrogen atoms are replaced with fluorine.
The term "lower haloalkyl", as used herein, refers to a CM alkyl group as defined herein in which one or more hydrogen atoms are replaced with a halogen atom.
The term "alkanesulfonamido," as used herein, refers to the group R-S(O)z-NH- where R is an alkyl group of 1 to 6 carbon atoms.
The term "alkoxy," as used herein, refers to the group R-O- where R is an alkyl group of 1 Jo 6 carbon atoms.
The term "perfluoroalkoxy," as used herein, refers to the group R-O where R is a perfluoroalkyl group of 1 to 6 carbon atoms.
The terms "monoalkylamino" and "dialkylamino," as used herein, respectively refer to -NHR and -NR*Rb, where R, R8 and Rb are each an independently selected C\^ alkyl group.
The terms "halogen" or "halo," as used herein, refer to chlorine, bromine, fluorine or iodine.
The term "protecting group" such as "hydroxyl protecting group" and "amine protecting group" are well understood by one skilled in the art. In particular one skilled in the art is aware of various protecting groups for use to protect hydroxyl and primary and secondary amine groups. Protecting groups, including include those described for example, in T. W. Greene and P. G. M Wuts, "Protecting Groups in Organic Synthesis"

(1991) provided that they are suitable for use in the chemistries described herein.
jfe
rwtieular examples of hydroxyl protecting groups include methyl, benzyl,
benzyloxymethyl, or allyl.
Amino protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Suitable amino protecting groups, taken with the -NH- moiety to which it is attached, include, but are not limited to, aralkyjamines, carbamates, allyl amines, amides, and the like. Examples of such groups include t-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxocarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, tnchloroacetyl, phenylacetyl, trifluoroacetyl, benzoyl, and the like. In other embodiments, an amino protecting group is acetyl, chloroacetyl, dichloroacetyl, tnchloroacetyl, phenylacetyl, or trifluoroacetyl. In still other embodiments, an amino group may be in protected form as a phthalimide or azide.
One of ordinary skill in the art will appreciate that certain moieties are incompatible with (i.e. may interfere with) certain chemical transformations as described herein. Thus, it will be understood that in for certain chemical transformations, certain moieties, e.g. a hydroxyl group or an amino group (primary or secondary), are preferably protected by a suitable protecting group as described herein prior to those transformations. By way of example, one of ordinary skill in the art would recognize that when R2 is -NH:, then that amino group is preferably protected prior to step S-5.
Suitable leaving groups are well known in the art, e.g., see, "Advanced Organic Chemistry," Jerry March, 5th Ed., pp. 445-448, John Wiley and Sons, R Y. Such leaving groups include, but are not limited to, halogen, alkoxy, sulfonyloxy, optionally substituted alkylsulfonyloxy, optionally substituted alkenylsylfonyloxy, optionally substituted arylsulfonyloxy. Examples of suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyl (mesyl), tosyl, triflyl, nitrophenylsulfonyl (nosyl), bromophenylsulfonyl (brosyl), and the like.
The compounds of the present invention may contain an asymmetric atom, and some of the compounds may contain one or more asymmetric atoms or centers, which may thus give rise to optical isomers (enantiomers) and diastereomers. In certain embodiments, the asymmetric atom is indicated with a "*". When shown without respect

to the stereochemistry, the present invention includes all optical isomers (enantiomers) and fcstereomers (geometric isomers); as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. Optical isomers may be obtained in pure form by standard procedures known to those Skilled in the art, and include, but are not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. It is also understood that this invention encompasses all possible regioisomers, and mixtures thereof, which may be obtained in pure form by standard separation procedures known to those skilled in the art, and include, but are not limited to, column chromatography, thin-layer chromatography, and high-performance liquid chromatography. Thus, the compounds of this invention include racematesi, enantiomers, or geometric isomers of the compounds shown herein.
It is recognized that atropisomers of the present compounds may exit. The present invention thus encompasses arropisomeric forms of compounds of formula I and II, as defined above, and in classes and sublcasses described above and herein. For definitions and an extensive discourse on atropisomers, see: Eliel, E.L. Stereochemistry of Organic Compounds (John Wiley & Sons, 1994, p 1142), which is incorporated herein by reference in its entirety.
The term "pharmaceutically acceptable salts" or "pharmaceutically acceptable salt" refers to salts derived from treating a compound of formula I with an organic or inorganic acid such as, for example, acetic, lactic, citric, cinnamic, tartan'c, succinic, fumaric, maleic, malonic, mandelic, malic, oxalic, propionic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, glycolic, pyruvic, methanesulfonic, ethanesulfonic, toluenesulfonic, salicylic, benzoic, or similarly known acceptable acids. In certain embodiments, the present invention provides the hydrochloride salt of a compound of formula I.
In some embodiments, certain reactions of the present invention are stereoselective. In other embodiments, certain reactions of the present invention are stereospecific.
The term "stereospecific" as used herein, is meant a reaction where starting materials differing only in their spacial configuration are converted to stereoisomerically distinct products. For example, in a stereospecific reaction, if the starting material is enantiopure (100% enantiomer excess "ee"), the final product will also be enantiopure.

Similarly if the starting material has an enantiomer excess of about 50%, the final product ( will also have about a 50% enantiomer excess.
By "stereoselective" as used herein, it is meant a reaction where one stereoisomer is preferentially formed over another. Preferably, the process of the present invention will produce a dihydrobenzofuran having an enantiomer excess of at least about 30%, more preferably at least about 40%, and most preferably at least about 50%, where enantiomer excess is the mole percent excess of a single enantiomer over the racemate.
"Enantiomer excess" or "% ee" as used herein refers to the mole percent excess of a single enantiomer over the racemate.
As used herein, the term "chiral non-racemic" is used interchangeably with "enantiomerically enriched" and signifies that one enantiomer makes up more than 50% of the preparation. In certain embodiments, the term enantiomerically enriched signifies that at least 60% of the preparation is one of the enantiomers. In other embodiments, the term signifies that at least 75% of the preparation is one of the enantiomers. In other embodiments, the term signifies that at least 95% of the preparation is one of the enantiomers. is meant a nonracemic mixture of chiral molecules. In some embodiments, the chiral non-racemic compounds have more than about 30% ee. In other embodiments, the compounds have more than about 50% ee, Or more than about 80% ee, or more than about 90% ee, or more than 95% ee, or more than 99% ee. The "*" in any chemical formula depicted herein indicates a chiral carbon.
The process of the present invention preferably produces dihydrobenzofuran derivatives having an enantiomer excess of at least about 30%, more preferably at least about 50%, and most preferably at least about 95%.
"Organic impurities" as used herein, refers to any organic by-product or residual material present in the desired dihydrobenzofuran product, and do not include residual solvents or water. "Total organic impurities" refer to the total amount of organic impurities present in the desired dihydrobenzofuran product. Percent organic impurities such as total organic impurities and single largest impurity, unless otherwise stated are expressed herein as HPLC area percent relative t the total area of the HPLC chromatogram. The HPLC area percent is reported at a wavelength where the desired product and maximum number of organic impurities absorb.
According to one aspect, the present invention provides a method for preparing an enantiomerically enriched compound of formula II:

(Figure Removed) or a pharmaceutically acceptable salt thereof, wherein:
q is one or two;
each of R2a and R3" is independently hydrogen, methyl, ethyl, 2-fluoroethyl, 2,2-
difluoroethyl or cyclopropyl; each R1* is independently hydrogen, halogen, OH, lower alkyl, lower alkoxy, lower
haloalkyl, lower haloalkoxy, or CN; Ar is thienyl, furyl, pyridyl, or phenyl, wherein Ar is optionally substituted with one or
more Rx subsituents; each Rx is independently selected from halogen, OH, lower alkyl, lower alkoxy, lower
haloalkyl, lower haloalkoxy, or CN; and y is 0,1,2, or 3.
" As defined generally above, the Ar group of formula II is thienyl, furyl, pyridyl, or phenyl, wherein Ar is optionally substituted with one or more subsituents independently selected from halogen, OH, lower alkyl, lower alkoxy, haloalkyl, haloalkoxy, or CN. In certain embodiments, the Ar group of formula II is unsubstituted phenyl. In other embodiments, the Ar group of formula II is phenyl with at least one substituent in the ortho position, to other embodiments, the Ar group of formula II is phenyl with at least one substituent in the ortho position selected from halogen, lower alkyl, lower alkoxy, or trifluoromethyl. According to another aspect the present invention provides a compound of formula II wherein Ar is phenyl di-substituted in the ortho and meta positions with independently selected halogen, lower alkyl, or lower alkoxy. Yet another aspect of the present invention provides a compound of formula II wherein Ar is phenyl di-subsituted in the ortho and para positions with independently selected halogen, lower alkyl, or lower alkoxy. In other embodiment, the present invention provides a compound of formula II wherein Ar is phenyl di-subsituted in the two ortho positions with independently selected halogen, lower alkyl, or lower alkoxy. Exemplary substituents on the phenyl moiety of the Ar group of formula II include OMe, fluoro, chloro, methyl, and trifluoromethyl.

In certain embodiments, the present invention provides methods for preparing a Jbmpound of formula Ilia or IHb:
(Figure Removed) or a pharmaceutically acceptable salt thereof, wherein each R1*, R2a, R3*,RX, y, and q are as defined above for compounds of formula II and in classes and subclasses as described above and herein.
According to another embodiment, the present invention provides methods for preparing a compound of formula IIIc or Hid:

(Figure Removed) or a pharmaceutically acceptable salt thereof, wherein each of Rla, R2*, R3*, Z, y, and q is as defined above for compound:* of formula II and in classes and subclasses as described above and herein.
The invention also concerns intermediates of the processes of the present invention.
In certain embodiments, the present invention provides a method for preparing a compound of formula I:
(Figure Removed) R2isCN,N3,orN(R3)(R4);
"dP and R4 are each independently hydrogen, an amine protecting group, C\^ alkyl, lower haloalkyl, 3-6 membered cycloaliphatic, or alkylcycloaliphatic, or R3 and R4 are taken together with the nitrogen to which they are attached to form a cyclic amine protecting group or a 3-6 membered saturated or partially unsaturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Cj.g alkyl, d-6 perfluoroalkyl, Ci-6 alkoxy, Ci-eperfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulrur, Ca-g alkenyl, Cj-6 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cj-g cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulrur; and
Ar is an optionally substituted 6-10 membered aryl or 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
wherein said method comprises one or more of the steps depicted in Scheme I above. In
certain embodiments, said method comprises all of the steps depicted in Scheme I above. It will be appreciated by one of ordinary skill in the art that, as used herein, the
term "cyclic amino protecting group" includes, for example, phthalimide and derivatives
thereof.
In some embodiments the invention provides a method for preparing a
compound of formula I-a:
(Figure Removed) wherein:
m is 0-3;
R2isCN,N3,orN(R3)(R4);
R3 and R4 are each independently hydrogen, an amine protecting group, C/^ alkyl, lower haloalkyl, 3-6 membered cycloaliphatic, or alkylcycloaliphatic, or R3 and R4 are taken together with the nitrogen to which they are attached to form a
cyclic amine protecting group or a 3-6 membered saturated or partially unsaturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Ci-g alkyl, C|-g perfluoroalkyl, Cj-6 alkoxy, d-e perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, C2-g alkenyl, Ci-6 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, C3-g cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and Ar is an optionally substituted 6-10 membered aryl or 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
comprising the steps of:
providing a compound of the formula F-l:
(Figure Removed) wherein:
mis 0-3;
R1 is hydrogen or a suitable hydroxyl protecting group;
ORy is a suitable leaving group;
R2isCN,N3,orN(R3XR4);
R3 and R4 are each independently hydrogen, an amine protecting group, Ci-e alkyl, lower haloalkyl, 3-6 membered cyclopliphatic, or alkylcycloaliphatic, or R3 and R4 are taken together with the nitrogen to which they are attached to form a cyclic amine protecting group or a 3-6 membered saturated or partially unsaturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Q.g alkyl, Cj-5 perfluoroalkyl, alkoxy, perfluoroalkoxy, 6-10 membered aryl, 6-10
membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, C2-8 alkenyl, alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cs cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and Ar is an optionally substituted 6-10 membered aryl or 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and
converting the compound of formula F-l to a compound of formula I-a or a
pharmaceutically acceptable salt thereof.
It will be appreciated by one of ordinary skill in the art that when one of, or
both of, R3 and R4 is hydrogen then nitrogen of R2 is preferably protected prior to
conversion of the hydroxyl group to a group of formula -ORy.
In some embodiments, the Ar group of either of formulae I or I-a is:
(Figure Removed) wherein: n is 0-5; and
each Z is independently Cl, F, CN, -OH, cyano, Cj-e alkyl, Cj^ perfluoroalkyl, C,^ alkoxy, or C i.-s perfluoroalkyl, alkoxy, or Ci_6 perfluoroalkoxy,
comprising the steps of:
(a) providing a compound of formula C-l:
(Figure Removed) wherein:
m is 0-3;
n is 0-5;
X is halogen;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chiorime, fluorine, CN, -OH, C|.g alkyl, Cj-s perfluoroalkyl, Ci-6 alkoxy, Cj-g perflvioroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Ca-g alkenyl, C|-g alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cj cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
each Z is independently Cl, F, CN, -OH, cyano, C^ alkyl, Ci-6 perfluoroalkyl, alkoxy, or Ci-e perfluoroalkoxy,
(b) converting the compound of formula C-l to a compound of formula C-2:
(Figure Removed) m is 0-3;
n is 0-5;
X' is halogen;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Cj.g alkyl, C|-6 perfluoroalkyl, Ci-6 alkoxy, C|-e perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Ca-g alkenyl, Cj-6 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cs-g cycloalipharic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
each Z is independently Cl, F, CN, -OH, cyano, Ci-s alkyl, C|-6 perfluoroalkyl, C|.6
alkoxy, or C1-6 perfluoroalkoxy,
(c) reacting the compound of formula C-2 with a chiral non-racemic epoxide of the fonnula:
wherein L is a leaving group, to produce a compound of formula D-l:
(Figure Removed) n is 0-5;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Cj.g alkyl, C|-6 perfluoroalkyl, Ci-6 alkoxy, Cj-g perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, C2-g alkenyl, Cj-6 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cs-g cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and each Z is independently Cl, F, CN, -OH, cyano, Cu alkyl, Ci_6 perfluoroalkyl, Ci_6
alkoxy, or C1-6 perfluoroalkoxy, (d) and converting the compound of formula to a compound of formula E-l.
In certain embodiments, the compound of formula D-l is converted to a compound of formula E-l by treating the compound of formula D-l with a compound of formula H-R2 and/or M-R2 optionally in the presence of a suitable solvent. In certain embodiments, R2 is -N(R3)(R4) and is phthalimlde. In other embodiments, R2 is N3.
In certain other embodiments, the preparation of a compound of formula E-l comprises: (a) providing a compound of the formula:
(Figure Removed) wherein:
m is 0-3;
n is 0-5;
X is halogen;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Q.g alkyl, C|-6 perfluoroalkyl, Cj-g alkoxy, Cj-s perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms
independently selected from nitrogen, oxygen or sulfur, Cj-g alkenyl, C|-6 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cs-g cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and each Z is independently Cl, F, CN, -OH, cyano, Ci-e alkyl, C\^ perfluoroalkyl, Cj.6
alkoxy, or C\-6 perfluoroalkoxy, (b) converting the compound of formula C-l to a compound of formula C-2:
(Figure Removed) wherein:
m is 0-3;
n is 0-5;
X' is halogen;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, C).g alkyl, Ci-g perfluoroalkyl, d-6 alkoxy, Cj-e perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Cj-g alkenyl, Cj-6 alkanesulfonamido, dialkylamino of I to 6 carbon atoms per alkyl moiety, C3-g cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
each Z is independently Cl, F, CN, -OH, cyano, Ci-6 alkyl, Cj-e perfluoroalkyl, Ci-6
alkoxy, or Ci-6 perfluoroalkoxy, (c) reacting the compound of formula C-2 with a chiral non-racemic epoxide of formula
wherein L is a leaving group, to produce at least one compound of formula:
(Figure Removed) (d) converting the compound of formula D-l or D'-l to a compound of formula E-l.
In certain embodiments, the compound of formula D-l or D'-l is converted to a compound of formula E-l by treating the compound of formula D-l or D'-l with a compound of formula H-R2 and/or M-R2 optionally in the presence of a suitable solvent. In certain embodiments, R2 is -N(R3)(R4) and is phthalimide.
In certain aspects, the invention concerns a process where the preparation of the compound of formula I comprises: (a) providing a compound of the formula:
(Figure Removed) wherein:
m is 0-3; :
R1 is hydrogen or a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Cj.g alkyl, Ci-6 perfluoroalkyl, Ci-6 alkoxy, d-6 perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having I to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Ca-g alkenyl, C|-6 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cj cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
each R8 is independently hydrogen or C|-6 alkyl, (b) contacting the compound of formula A with a compound of formula A-l

(Figure Removed) wherein: n is 0-5; each Z is independently Cl, F, CN, -OH, cyano, C|-6 alkyl, Ci-6 perfluoroalkyl, Ct_6
alkoxy, or C1-6 perfluoroalkoxy; and
X1 is Cl, Br, I, triflyloxy (-OS02CF3) or other perfluoroalkylsulfonyloxy, in the presence of a palladium catalyst to produce a compound of the formula B-1:
(Figure Removed) wherein:
m is 0-3;
n is 0-5;
Rl is hydrogen or a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, C|.g alkyl, C|-6 perfluoroalkyl, d-6 alkoxy, Cj-6 perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Cj-g alkenyl, Cj-6 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cs-g cycloaliphatic, or 3-8 membered h^terocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
each Z is independently Cl, F, CN, -OH, cyano, Cu alkyl, CM perfluoroalkyl, Ci-6
alkoxy, or Ci-e perfluoroalkoxy, and
(c) contacting the compound of formula B-1 with a halogenating agent to produce a compound of formula C-l:
(Figure Removed) wherein: m is 0-3; n is 0-5; X is halogen;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Ci.g alkyl, d-e perfluoroalkyl, alkoxy, perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, alkenyl, alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, C3-g cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and each Z is independently Cl, F, GN, -OH, cyano, alkyl, perfluoroalkyl,
alkoxy, or perfluoroalkoxy.
In certain embodiments, R1 is Cj-4 alkyl. In some embodiments, X1 is Br. In
certain embodiments, step (b) above (the Suzuki coupling step) is performed using conditions that are well known in the art. See, for example, Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95,2457. In certain embodiments, the Suzuki coupling at step (b) is performed in the presence of a palladium containing compound. In other embodiments, the palladium containing compound is Pd(PPhj)4. The reaction may also be performed in the presence of a base. In certain embodiments, the base is MOH, M2CO3, or MaPO,,, wherein each M is independently an alkali metal. In some embodiments, the alkali metal is sodium, potassium, or lithium. In other embodiments, step (b) is performed in the presence of NaOH. The reaction is optionally carried out in the presence of a solvent. Suitable solvents for the coupling at step (b) include dimethoxyethane, toluene, ethanol, isopropanol, methanol, and tetrahydrofuran (THF). In certain embodiments, the suitable solvent for the coupling step of (b) includes water. In certain embodiments, the Suzuki
coupling reaction is carried out at a temperature in the range of about 20 °C to about the temperature sufficient to reflux the solvent or mixture of thereof. In other embodiments, the coupling reaction is carried out at about 60 to about 90 °C. In still other embodiments, the coupling reaction is carried out at about 70 to about 80 °C.
Some embodiments of the invention concern a process where the conversion of the compound of formula C-1 to the compound of formula D-l comprises: (a) contacting the compound of formula C-1 with a Grignard reagent or magnesium metal to form a compound of formula C-2:
(Figure Removed) wherein:
m is 0-3;
n is 0-5;
X' is halogen;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, CM alkyl, Q-e perfluoroalkyl Ci-s alkoxy, Cj-e perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Cj-g alkenyl, Ci-« alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Cj cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
each Z is independently Cl, F, CN, -OH, cyano, C].6 alkyl, Cj^ perfluoroalkyl,
alkoxy, or perfluoroalkoxy, (b) contacting the compound of formula C-2 with a chiral non-racemic epoxide of formula
wherein L is a leaving group, to form a compound of the formula D'-l:
(Figure Removed) In certain embodiments, the step of contacting a compound of formula C-2 and
occurs in the presence of a copper salt. In some embodiments, this step occurs at a temperature of about -15 °C to about -35 °C. In yet other embodiments, this step occurs at a temperature of about -20 °C to about —25 °C. In some embodiments, the copper salt is CuCN, LijCuCU or Cul. According to one embodiment, the copper salt is Cul. In certain embodiments, the Grignard reagent is isopropyl magnesium chloride.
Some embodiments of the invention concern a process where the compound of formula £ is:
(Figure Removed) wherein:
m is 0-3;
n is 0-5;
R1 is hydrogen or a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, C].g alkyl, Ct-6 - perfluoroalkyl, Ci-6 alkoxy, Cpe perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, C2-g alkenyl, Ci-e alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, Ca-g cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and each Z is independently Cl, F, CN, -OH, cyano, Ci-6 alkyl, Cj.6 perfluoroalkyl, Cj.6 alkoxy, or Cj.6 perfluoroalkoxy.
In certain of these processes the compound of formula E-2 is contacted with RyCl and a suitable base to produce a compound of formula F-2:
(Figure Removed) wherein R1, n, m, Y, and Z are as defined above and -ORy is optionally substituted alkylsulfonyloxy, optionally substituted alkenylsulfonyloxy, or optionally substituted arylsulfonyloxy. Examples of such Ry groups include methanesulfonyl (mesyl), tosyl, triflyl, nitro-phenylsulfonyl (nosyl), and bromo-phenylsulfonyl (brosyl).
In certain embodiments, the compound of formula F-2, as defined herein, is contacted with a methyl ether cleaving agent to produce a compound of formula G-2:
(Figure Removed) wherein n, m, Y, and Z are as defined herein.
In certain embodiments, the phthalimide moiety of compound G-2 is removed to form a compound of formula I-a:
(Figure Removed) wherein n, m, Y, and Z are as defined herein. It will be appreciated by one of ordinary skill in the art that when other amino protecting groups are utilized, i.e. instead of the phthalimide group, then those protecting groups can be removed by suitable means to form a compound of formula I-a.
In some embodiments, the methyl ether cleaving agent is selected from Bis, BBrj, Alls, or AlBrs. In other embodiments, said agent is BBrj.
In certain embodiments, the phthalimide moiety of the compound of formula G-2 is converted to a compound of formula I*a in a process comprising contacting the compound of formula G-2 with a hydrazine. In some embodiments, the hydrazine is hydrazine hydrate.
In certain preferred embodiments, the hydrazine contacting step occurs in the presence of an alcohol or THF solvent or mixtures thereof.
In some aspects, the invention relates to processes where the compound of formula I is
(Figure Removed)
or a pharmaceutically acceptable salt thereof.
As described generally above, the present invention provides methods for preparing a compound of formula I:
(Figure Removed) wherein:
is 0-3;
lPisCN,N3,orN(R3)(R4);
R3 and R4 are each independently hydrogen, an amine protecting group, C|-e alkyl, lower haloalkyl, 3-6 membered cycloaliphatic, or alkylcycloaliphatic, or R3 and R4 are taken together with the nitrogen to which they are attached to form a cyclic amine protecting group or a 3-6 membered saturated or partially unsaturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Ci-g alkyl, Ci-6 perfluoroalkyl, Cj-g alkoxy, Ci-g perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Cz-g alkenyl, C| -5 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, €3-8 cycloaliphatic, or 3-8 membered heterocyCloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
Ar is an optionally substituted 6-10 membered aryl or 5-10 membered heteroaryl having l-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
It will be appreciated that when the R2 group of formula I is CN, the cyano
group may be reduced to form a compound of formula F:
(Figure Removed) wherein m, Y, and Ar as defined herein.
Thus, another embodiment of the present invention provides a method for preparing a compound of formula F:(Figure Removed) wherein: m is 0-3;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Ci-g alkyl, C|-e perfluoroalkyl, C\-6 alkoxy, Ci-e perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 rnembered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Ca-g alkenyl, €1-5 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, C$ cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and Ar is an optionally substituted 6-10 membered aryl or 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
comprising the steps of:
(a) providing a compound of formula D:
(Figure Removed) wherein:
m is 0-3;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Cj.g alkyl, C|-$ perfluoroalkyl, Ci-g alkoxy, C|-s perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Cj-g alkenyl, Cr6 alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, C3-g cycloaliphatic, or 3-8 membered heterocycloalkyl having I to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
Ar is an optionally substituted 6-16 membered aryl or 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
(b) treating said compound of formula D with a compound M-CN, wherein M is a suitable metal, to form a compound of formula H:
(Figure Removed) wherein:
m is 0-3;
R1 is a suitable hydroxyl protecting group;
each Y is independently hydrogen, chlorine, fluorine, CN, -OH, Cj.g alkyl, C|-6 perfluoroalkyl, Ci-s alkoxy, Ci-g perfluoroalkoxy, 6-10 membered aryl, 6-10 membered aryloxy, 5-10 membered heteroaryl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen or sulfur, Ca-g alkenyl, C|-s alkanesulfonamido, dialkylamino of 1 to 6 carbon atoms per alkyl moiety, €3-8 cycloaliphatic, or 3-8 membered heterocycloalkyl having 1 to 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; and
Ar is an optionally substituted 6-10 membered aryl or 5-10 membered heteroaryl having 1 -4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
(c) converting the hydroxyl group of compound H to a suitable leaving group,
(d) cyclizing the resulting compound to form a compound of formula J:

(Figure Removed) wherein m, Ar, and Y are as defined herein; and (e) reducing the cyano group to form a compound of formula P.
In other aspects, the invention concerns the products,,including intermediates and by-products, of the processes described herein.

In certain embodiments, compounds of the present invention are synthesized according to the following synthetic Scheme II below. One skilled in the art will recognize that this asymmetric synthesis could be used to synthesize the opposite enantiomer in enantiomeric excess using the appropriate glycidyl tosylate.
(Figure Removed) Each of the above reaction steps are described more generally below. One skilled in the art will recognize that these reaction steps described below and as illustrated in Scheme II can be generally applied to form compounds of the present invention.
Catalyst and reaction conditions for the Suzuki reaction of Scheme III below are well known in the art. See, for example, Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95,2457. In certain embodiments, the reaction shown in Scheme III is performed in the presence of a palladium containing compound. In certain embodiments, the palladium containing compound is Pd(PPha)4. The reaction may also be formed in the presence of a base. In certain embodiments, the base is MO|H, MaCCh, or MsPO*, where M is an alkali metal. In some embodiments, the alkali metal is sodium, potassium, or lithium. The reaction may be carried out in the presence of a solvent. Preferred solvents include dimethoxyethane, toluene, ethanol, isopropanoj, methanol, tetrahydrofuran (THF) and

mixtures thereof. In other embodiments, the additionally comprises contains water. In certain embodiments, the reaction is carried out at a temperature in the range of about 40 °C to about the temperature for refluxing the solvent. Scheme III
(Figure Removed) In certain preferred embodiments, the brominating agents used in Scheme IV below is bromine or any of the compounds containing N-Br group (e.g., N-bromosuccinimide). Other brominating agents are known to those skilled in the art. In certain embodiments, one or more additives are used in the reaction. These additives include inorganic acid such as HaSO4 (used with a N-Br brominating agent), Lewis acid, or AcONa (used with bromine). Preferred solvents for the reaction include dioxane, THF, acetic acid, or a chlorinated solvent. Chlorinated solvents include CH2Cl2, CHCh, CCU, dichloroethane, or others. In some embodiments, the reaction is preformed at a temperature of about 18 °C to about solvent reflux. In other embodiments, the additive is p- toluene sulfonic acid and the solvent is acetic acid or formic acid. Scheme IV

(Figure Removed) In some embodiments, the magnesium containing reagent used in Scheme V below is Mg metal or RMgX, where R is alkyl and X is halogen. Preferred solvents include THF and dialkyl ether. Preferred catalysts include copper salts. Such copper salts are preferably used in an amount of about 1 to 100 mol % relative to the starting material. In certain embodiments, the copper salt is Cul. Preferred bases used in this scheme include MOH and MjCOs, where each M is an alkali metal. "OTs" in Scheme V represents the leaving group tosylate. The base can be used neat or as an aqueous solution. In certain embodiments, the Grignard formation is carried out at a temperature of from about -50 °C to about -10 °C. In other embodiments, the reaction is performed at

below about -18 °C. In certain embodiments the alkylation step is performed at about 0 °C
about 50 °C. In other embodiments, as more fully described in Scheme X, epoxide formation is not necessary and thus that step (as described below in Example 3) can be eliminated. Scheme V

(Figure Removed) In the reaction shown in Scheme VI below, Pht-NH and Pht-NM represents phthalimide and its salt where M is a metal respectively. In some embodiments of Scheme VI, the phthalimide reagent does not need to be a mixture and may be for example only Pht-NM as more fully described in Scheme X. One skilled in the art will recognize that other reagents may be used that provide a protected amine or a nonreactive amine such as those having the formula HNR3R4 and/or MNR3R4, where R3 and R4 are defined as previously herein. In certain embodiment, M is a Group I metal. In some embodiments, M is K, Li, or Na. In some preferred embodiments, the amount of Pht-NH is greater or equal to 1 equivalent of Pht-NM. In certain embodiments, about 0.1 to about 1 equivalents of Pht-NM per equivalent of Pht-NH is preferred. Preferred solvents for this step include DMF, DMSO and NMP. In some embodiments, the reaction is performed at a temperature of from about 40 °C to about 130 °C. Scheme VI
(Figure Removed) In Scheme VII below, the base is in certain embodiments any tertiary amine or j, where M is a Group I metal. Preferred solvents include toluene or any chlorinated solvent, THF, and dialkyl ether. In some embodiments, the preferred reaction temperature

is from about 0 °C to about 60 °C. In certain embodiments, ORy is a mesylate ("OMs") Hiving group. Scheme VII
(Figure Removed) For the reaction shown in Scheme VIII below, a methyl ether cleaving agent such as 8813 is used. Other cleaving agents that may be used include those described in Greene, T. W., Wuts, P. G. M., Protective Groups in Organic Synthesis, 3rd Ed.; Wiley & Sons, New York, 1999. Preferred solvents include any chlorinated solvent or toluene. In some embodiments, preferred reaction temperatures are from about -10 °C to about 25 °C. Scheme VIII
(Figure Removed) If a protected amine is used in the above reaction scheme (where R3 and/or R4 are amine protecting group(s)), preferably the compound formed after cyclization is deprotected. Scheme IX below, shows one such method for deprotection to form the compound of formula I where R3 and R4 are hydrogen. In certain preferred embodiments of Scheme IX, the phthalimide amine protecting group is removed using reagent R'NHNHj where R' is H, Q-s alkyl, or aryl. Preferred solvents for the deprotection step include THF and R"OH, where R" is Ci to Ce alkyl. Preferred temperatures for the deprotection step is from about 40 °C to about solvent reflux. Preferred solvents for the salt formation include dialkyl ether or R"OH where R" is Ci to Ce alkyl. A pharmaceutically acceptable salt may optionally be formed of formula IV using any
pharmaceutically acceptable acid such as HC1. Preferred temperatures for the salt
rmation include about 18 °C to about 30 °C. Scheme IX
(Figure Removed)
A method for making 2(R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzoftiran hydrochloride is shown in Scheme X below. One skilled in the art will recognize that this asymmetric synthesis could be used to synthesize the corresponding "S" enantiomer in enantiomeric excess using the appropriate glycidyl tosylate in Step 3a below. Each Step of Scheme X is discussed in more detail below.
(Figure Removed) In Step la of Scheme X above, 2,6H-dichlorobromobenzene and 2-methoxy-5-fluoro-benzeneboronic acid are reacted via a Suzuki coupling reaction to form 2',6'-dichloro-5-fluoro-2-methoxy-biphenyl. The coupling is carried out in the presence of a palladium catalyst and a base. The coupling is preferably carried out in the presence of a solvent such as dimethoxyethane, ethanol, tetrflhydrofuran, isopropanol, or methanol, or combinations thereof.
In an embodiment of the invention, an aqueous solution of sodium hydroxide is added to a mixture of 2,6-dichlorobromobenzene, 2-methoxy-5-fluorobenzeneboronic acid, tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) and dimethoxyethane (DME). The molar ratio of 2-methoxy-5-fluoro-benzeneboronic acid to dichlorobromobenzene, may be for example from about 1:1 to about 2:1. Preferably NaOH is used in an amount
of from about 2 to about 5 equivalents based on the dichlorobromobenzene. The Palladium catalyst may be used in an amount of from about 1% to 5% based on the dichlorobromobenzene. In another embodiment, other bases may be used in Step la, such as KOH in place of NaOH. For minimization of reaction by-products, the reaction temperature is preferably at least about 50 °C more preferably about 60 °C to about 90 °C and most preferably from about 70 °C to about 80 °C. After the coupling reaction is completed to the desired extent, the mixture is cooled and phases are separated. The reaction mixture is concentrated and an organic solvent such as heptane is added. Purification of the 2',6'-dichloro-5-fluoro-2-methoxy-biphenyl may be carried out for example by washing with water, contacting the resulting mixture with silica gel followed by filtration. The 2',6'-dichloro-5-fluoro-2-methoxy-biphenyl may be concentrated as described below and used directly for Step 2a. The reaction yield of the Step la is preferably about 88-92%.
In Step 2a of Scheme X, the 2',6'-dichloro-5-fluoro-2-methoxy-biphenyl is brominated using a brominating agent in the presence of an organic acid. In an embodiment, N-bromosuccinimide (NBS) is used as the brominating agent and para-toluenesulfonic acid (pTSA) is used as the organic acid. A reaction solvent may also be used, for example, acetic acid or formic acid.
In one embodiment of step 2a, a solution of 2',6'-dichloro-5-fluoro-2-methoxy-biphenyl is concentrated under vacuum. Optionally a solvent such as acetic acid or formic acid is added and removed as a chase to further purify the intermediate. To the 2',6'-dichloro-5-fluoro-2-methoxy-biphenyl is added N-bromosuccinimide (NBS), para-toluenesulfonic acid (pTSA) and acetic acid. The amount of NBS is preferably from about 1 eq to about 1.5 eq. based on the moles of 2',6'-dichloro-5-fluoro-2-methoxy-biphenyl. The amount of pTSA is preferably from about 0.1 eq to about 0.5 eq. based on the moles of 2',6'-dichloro-5-fluoro-2-methoxybiphenyl. The suspension is preferably heated to about 50 °C to about 55°C and stirred for about 24 hours. The reaction is quenched with an aqueous solution of sodium metabisulfite and the product is collected by filtration. The yield of the bromination is preferably about 88% to about 92%. The overall yield of Steps la and 2a is preferably about 77% to about 85%. In another embodiment, formic acid could be used in place of acetic acid. The resulting 3-bromo-2',6'-dichloro-5-fluoro-2-methoxy-biphenyl can be used directly for Step 3a or alternatively can be recrystallized from a suitable solvent such as a mixture of acetic acid and water or heptanes.
In Step 3a(i) of Scheme X, 3-bromQ-2',6'-dichloro-5-fluoro-2-
methoxybiphenyl is reacted with a Grignard reagent to form a compound of formula C-2 where Y is 5-fluorine, Z is chlorine at the 2- and 6-positions, Rl is methyl, and X' is Cl arid/or Br. In an embodiment, the Grignard reagent is formed by adding dropwise isopropyl magnesium chloride in tetrahydrofuran (THF) solution to a cold (e.g., about - 6 to -3 °C) solution of 3-bromo-2',6'-dichloro-5-fluoro-2-methoxy-biphenyl in THF. In an embodiment, the resulting solution stirred at about -3 to about 2 °C for about 2 to about 3 hours.
In step 3a(ii) of Scheme X, the resulting Grignard reagent is reacted with (2S)-(-f)-glycidyl tosylate in the presence of a copper catalyst. In an embodiment, the Grignard reagent of formula C-2 is preferably cooled to about -25 to about -30 °C, and Cul is added. Preferably, Cul is added in an amount of about 0.01 eq. to about 0.1 eq based on the 3-bromo-2',6'-dichloro-5-fluoro-2-methoxybiphenyl. The resulting mixture may be stirred for example for about 30 minutes to about 45 minutes in this temperature range. A solution of (2S)-(+)-glycidyl tosylate in THF is added dropwise to the mixture. The (2S)-(+)-glycidyl tosylate is preferably added in an amount of from about 1 equivalents to about 1.5 equivalents based on the 3-bromo-2',6'-dichloro-5-fluoro-2-methoxy-biphenyl. Preferably during this step, the reaction temperature is maintained at about —29 °C to about -21 °C. Following addition of the (2S)-(+)-glycidyl tosylate, the reaction mixture may be stirred, for example, for an additional 3 to 4 hours. Upon completion of the reaction, the reaction may be quenched with, for example, an ammonium chloride solution. The organic layer is separated and preferably is further washed, extracted with a solvent such as toluene, and concentrated to obtain one or more of the following Grignard reaction product intermediates as an oil:

(Figure Removed) One of ordinary skill in the art would appreciate that, unlike in Scheme I, it is not necessary to contact the resulting Grignard reaction product intermediate with NaOH as shown in Example 3 to convert the hydroxytosylate to the corresponding epoxide.
Instead, the above Grignard reaction product intermediates may be reacted directly in Step 4a, i.e. without isolation.
In step 4a of Scheme X above, the Grignard reaction product intermediates are contacted with potassium phthalimide in the presence of a solvent to form (2S)-3-[5-fluoro-3-(2,6-dichlorophenyl)-2-methoxyphenyl]-l-A'-phthalimidopropan-2-ol.
In an embodiment, the Grignard reaction product intermediates are dissolved in N,N-dimethyl formamide (DMF) and contacted with potassium phthalimide. In one embodiment, about 1 to about 2 equivalents of potassium phthalimide is used based on starting bromo-2',6'-dichloro-5-fluoro-2-methoxy-biphenyl. In another embodiment, the contacting is carried out at a temperature of about 80 °C to about 86 °C. The contact time is preferably about 8 to about 10 hours. The resulting crude (2S)-3-[5-fluoro-3-(2,6-dichlorophenyl)-2-methoxyphenyl]-l-A/r-phthalimidopropan-2-ol may be purified using techniques such as washing the organic layer with suitable solvents, distillation and recrystallization. Preferably the yield based or* starting bromo-2',6'-dichloro-5-fluoro-2-methoxy-biphenyl yield is about 57% to about 67%.
In step 5a of Scheme X, (2S)-3-[5-fluoro-3-(2,6-dichlorophenyl)-2-methoxyphenyl]-l-JV-phtbalimidopropan-2-ol undergoes alcohol mesylation to form (2S)-3-[3-(2,6-dichlorophenyl)-5-fluoro-2-methoxyphenyl]-l-N-phthalimidopropan-2-yl methanesulfonate. In an embodiment, to a solution of (2S)-3-[5-fluoro-3-(2,6-dicWorophenyl)-2-methoxyphenyl]-l-^V-phthaUmidopropan-2-ol in THF is added triethylamine (TEA) followed by dropwise additions of methanesulfonyl chloride (MsCl). la one embodiment, the TEA is added in an amount of from about 1 to about 1.5 equivalents based on (2S-3-[5-fluoro-32,6-dichlorophenyl)-2-methoxyphenyl]-l-JV-phthalimidopropan-2-ol starting material. In another embodiment, the MsCl is added in an amount of from about 1 to about 1.5 equivalents based on (2S)-3-[5-fluoro-3-(2,6-dichlorophenyl)-2-methoxyphenyl]-l-A^-phthalimidopropan-2-oI starting material. In certain embodiments, the TEA and MsCl are both added in an amount of about 1.5 equivalents. In another embodiment, instead of using THF, other solvents such as dichloromethane and acetonitrile may be used. The reaction is preferably carried out at room temperature until completion, for example from about 1 to about 2 hours. After the reaction is completed, water is added to the mixture. Preferably, the resulting white suspension is stirred at room temperature for about 2 hours. The (2S)-3-[3-(2,6-dichIorophenyl)-5-fluoro-2-methoxyphenyl]-l-N-phthalimidopropan-2-yl
ethanesulfonate may be isolated by filtration. Preferably the (2S)-3-[3-(2,6-dichlorophenyl)-5-fluoro-2-methoxyphenyl]-l-N-phthalimidopropan-2-yl methanesulfonate is produced in a yield of about 95 %. Optionally, the (2S)-3-[3-(2,6-dichlorophenyl)-5-fluoro-2-methoxyphenyl]-l-N-phthalimidopropan-2-yl methanesulfonate may be recrystallized again in solvents such as THF or mixtures of solvents such as THF and water. However, the enantiomeric excess may decrease, for example, from 90% to 80% after one recrystaljization.
In Step6a, (2S)-3-[3-(2,6-dichlorophenyl)-5-fluoro-2-methoxyphenyl]-l-N-phthalimidopropan-2-yl methanesulfonate is subjected to a ring closing reaction using a methyl ether cleavage to form 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-(N-phthalimidomethyl)benzofuran. In an embodiment, to a stirring suspension of (2S)-3-[3-(2,6-dichlorophenyl)-5-fluoro-2-methoxyphenyl]-l-N-phthalimidopropan-2-yl methanesulfonate in toluene is added boron tribromide (BBra). Preferably, BBr3 is added in an amount of about 1 eq. to about 1.5 eq. based on (2S)-3-[3-(2,6-dichlorophenyl)-5-fluoro-2-methoxyphenyl]-l-N-phthalimidopropan-2-yl methanesulfonate starting material. The reaction mixture is preferably stirred at a reaction temperature of about 18 "C to about 22 °C until the desired conversion of starting material has been reached. Preferably such a conversion is reached in about 18 hours or less. In an alternative embodiment, dichloromethane may be used instead of toluene. In such an embodiment the reaction temperature may be from about -78 °C to about room temperature (e.g., about 23 °C). Following completion of the reaction, the' 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-(N-phthalimidomethyl)benzofuran may be isolated for example by cooling the mixture to about 0 °C to about 5 °C and adding methanol to form a suspension. The suspension may be concentrated and additional methanol may be added for purifying and filtering the 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-(N-phthalimidomethyl)benzofuran. Optionally, the product may be recrystallized again in solvents such as toluene or mixtures of solvents such as toluene and heptanes. The enantiomeric excess may improve for example from 93% to over 99% after one or two recrystallizations.
[00101) In Step 7a of Scheme X, the phthalimide protecting group is removed from 2R-7-(2>6-dichlorophenyl)-5-fluoro-2,3-dihydro-2^(N-phthalimidomethyl)benzofurantoform 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzofuran.
In an embodiment, to a stirring suspension of 2R-7-(2,6-dichlorophenyl)-5-
jRk)ro-2,3-dihydro-2-(N-phthaJimidomethyl)ben2ofuran in a solvent mixture of ethanol and water, hydrazine hydrate is added. In one embodiment, the volume ratio of ethanol to water is from about 4 :1 to about 3 :2. In another embodiment, the hydrazine hydrate is added in an amount of about 2 eq. to about 5 eq. based on 2R-7-(2,6-dichloropheriyl)-5-fluoro-2,3-dihydro-2-(N-phthalimidomethyl)benzofuran starting material. Preferably, the reaction mixture is heated to reflux and stirred until the desired conversion of starting material is reached. In one embodiment, the reaction time is about 2 hours. Following completion of the reaction, the resulting 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzofurane may be isolated by adding water and t-butylmethyl ether (TBME) to the reaction mixture and separating the phases and washing the aqueous with TBME. The combined organic layers are washed with 1% sodium hydroxide followed by water.
In Step 8a of Scheme X, the crude 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzofuran is converted to a hydrochloride salt and purified. In an embodiment, the crude 2R-7-(2,6-dichIorophenyl)-5-fluoro-2,3-dihydro-2-armnomethylbenzoftiran in TBME is concentrated under reduced pressure and TBME is replaced by isopropanol. To the 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzofuran solution is added a solution of hydrochloric acid in isopropanol (IP A). Preferably the hydrochloric acid is present in an amount of about 1 to about 1.5 equivalents based on the molar amount of 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydrO'2-aminomethylbenzofuran. To the IPA suspension is added water. The mixture is preferably heated to about 75 °C to about 78 °C to give a clear solution. This solution is gradually cooled and concentrated. The product is isolated by filtration. Preferably, the overall yield based on the starting amine is about 82 % to about 92%. The enantiomeric excess may improve for example from 97.8% in the starting material to 98,6% in the hydrochoride salt. Optionally, the product may be recrystallized again in solvents such as IPA or mixtures of solvents such as IPA and water.
The resulting 2R-7-(2,6-dichIorophenyJ)-5-fluoro-2,3-dihydro-2-aminomethylbenzofuran hydrochloride in some embodiments form needle shaped crystals. These crystals may be milled as shown in Step 9a if desired to aid in further processing.
In other embodiments of the present invention, the process of the present invention provides compositions containing (2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-

hydro-2-aminomethylbenzoftiran hydrochloride. In some embodiments, the compositions contain (2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzofuran hydrochloride in an amount of at least about 97, 97.5, 98, 98.5, 99,99.5,99.8 weight percent where the percentages are based on the total weight of the composition.
In some other embodiments, the composition containing (2R)-7-(2,6-dichIorophenyl)-5-fluoro-2,3 -dihydro-2-aminamethylbenzoftiran hydrochloride contains from about 9.5 weight percent to about 11.6 weight percent HCI as measured by ion chromatography based on the total weight of the composition. In other embodiments, the composition containing (2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzofuran hydrochloride contains from about 10 weight percent to about 10.5 weight percent HCI as measured by ion chFomatography based on the total weight of the composition.
In other embodiments, the composition containing (2R)-7-(2,6-
dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzofuran hydrochloride preferably contains no more than about 2.0 area percent HPLC of total organic impurities and more preferably no more than about 1.5 area percent HPLC total organic impurities relative to the total area of the HPLC chromatogram. In other embodiments, the composition containing 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzoruran hydrochloride preferably contains no more than about 0.6 area percent HPLC of any single impurity and more preferably no more than about 0.5 area percent HPLC of any single impurity relative to the total area of the HPLC chromatogram. According to another embodiment, the composition containing 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzoruran hydrochloride preferably contains no more than about 0.2 area percent HPLC of any single impurity relative to the total area of the HPLC chromatogram. According to yet another embodiment, the composition containing 2R-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzoruran hydrochloride preferably contains no more than about 0.2 area percent HPLC of total impurities relative to the total area of the HPLC chromatogram.
In yet other embodiments of the invention, the composition containing (2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzoruran hydrochloride preferably contains no more than about the following residual solvents individually alone or in any combination: 0.5 weight percent THF, 0.5 weight percent ethanol, 0.5 weight

uereent isopropylacetate, 0.5 weight percent heptane, 0.5 weight percent hexanes, 0.5 weight percent isopropanol and/or 0.5 weight percent /-butyl methyl ether based on the total weight of the composition. In other embodiments, the composition containing (2R)-7-(2,6-dichlorophenyl)-5-fluoro-2>3-dihydro-2-aminomethylbenzofuranhydrochloride preferably contains no more than about 0.03 weight percent to about 0.04 weight percent ethanol and/or 0.04 weight percent to 0.05 weight percent isopropanol.
In other embodiments, the present invention is directed to intermediates. In certain other embodiments compositions comprising each of the intermediates and one or more organic impurities and/or one or more residual solvents are provided. Examples of intermediates include:
(Figure Removed) EXPERIMENTAL
Another method for,the synthesis of 2R-(-)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-2-aminomethylbenzofuran hydrochloride is illustrated Scheme XI and more fully described in the following examples:
Scheme XI
(Figure Removed) To a solution of NaOH (54 g, 1.35 mol) in water (400 mL) heated to 60 °C was added dimethoxyethane (400 mL), then dichlorobromobenzene (Aldrich, 60 g, 0.267 mol) and boronic acid (50 g, 0.294 mol). To the resulting stirred emulsion, solid Pd(PPh3)( (9.5 g, 8.2 mmol) was added and washed down with 100 mL of DME. The greenish mixture was heated at reflux (ca. 80 °C) while being stirred mechanically. The course of reaction was monitored by HPLC. After 2 hr, 9.0 g (0.053 mol) of additional boronic acid and 2.0 g (1.7 mmol) of the catalyst were added to the reaction mixture and the heating was continued for 16 hr longer. More boronic acid (5.8 g, 0.034 mol) and the catalyst (0.5 g, 0.4 mmol) were added at that point and the mixture was kept at reflux for 7 hr longer (23 hr was total reaction time).

The heating was stopped and 600 niL of heptane and 300 mL of water were added. The mixture was allowed to cool to room temperature and then was filtered through Celite. The layers were separated, the organic layer was washed with water, three times with brine, dried with MgS04 and filtered through a pad of Magnesol. The clear colorless solution was concentrated on a rotary evaporator to a colorless oil (weight 72 g). The oil was triturated with 120 mL of heptane which caused crystallization of a white solid. The mixture was left in a refrigerator overnight, the separated crystals were filtered and dried in air. Yield 51 g, 93% pure. The major impurity was determined to be the homo-coupling product 13. Additional recrystallization of the material from heptane gave crystals of 98% purity. Yield 45 g (62%) as white crystals.

Example 2 l-Methoxy-2-bromo-4-fluoro-2',6'-dichlorobiphenyl

(Figure Removed) To a magnetically stirred solution of the biarene 3 (38.0 g, 0.140 mol) in 190 mL of dioxane placed into a 500-mL round-bottom flask equipped with a temperature probe, cone, sulfuric acid (38 mL) was added slowly. To the warm solution, solid NBS (26.7 g, 0.150 mol) was added in one portion (no exothermic heating was observed here) The resulting solution was heated in a mantle at 50 °C. The reaction progress monitored by HPLC. After 18 hr, only trace amount of the Starting arene was detected.
The reaction mixture was allowed to qool to r.t., then it was poured onto 400 g of ice. Heptane (100 mL) was added and the mixture was transferred to the separatory runnel. The aqueous layer was separated and extracted with additional portions of heptane (2 x 100 mL). Combined organic solutions were Washed once with water (30 mL), then aq. Na2S2Oj solution, and, finally, with 1 M aq. NaOH solution (2 x 30 mL). Light-yellow clear organic solution was dried with MgSCM, filtered through a cotton plug and evaporated in vacuum. The resulting yellow oil was re-dissolved in 55 mL of heptane.
The first batch of crystals (25.5 g) slowly separated from the heptane solution at r.t. and was filtered and dried in air. Purity 98% (HPLC at 215 nm), white crystals. M.p. 67-69 °C.

The second batch of the product (13.9 g) was isolated from the mother liquor oy chilling it in a dry-ice-acetone bath, filtering off the precipitated solid and drying it in a vacuum desiccator over CaS04. Purity 97% (HPLC area% at 215 nm), white amorphous powder. M.p. 47-56 °C. Total yield 39.4 g (80%). *H NMR (300 MHz, CDC13) 5: 7.42 (m, J - 8.1 Hz, 2H), 7.39 (dd, J » 3.0,7.7 Hz, 1H), 7.30 (dd, J = 8.1 Hz, 1H), 6.86 (dd, J = 3.0, 8.0 Hz, 1H), 3.56 (s, 3H).
Example 3 2-[5-Fluoro-3-(2,6-dichlorophenyl-2-metboxybenzyl]oxirane

(Figure Removed)

Generation of the Grignard reagent. Aryl bromide (25.0 g, 71.4 mmol) was placed into a 500-mL flask equipped with a magnetic stirre*. nitrogen inlet, temperature probe and A rubber septum. The flask was purged excessively with nitrogen, then left under positive nitrogen pressure. Dry THF (100 mL) was transferred into the flask via a syringe. The -solution was chilled in an ice bath to 2 °C.
A solution of i-PrMgCl in THF (1.9 M, Aldrich, 39.5 mL, 75 mmol) was added slowly to the solution in the flask via a syringe (20 minutes addition time, the temperature was maintained between 2 and 6 °C). The resulting yellowish solution was left in the bath for 18 hr allowing it to reach room temperature.
Reaction with glycidyl tosylate. The solution of the Grignard reagent was chilled to -30 °C by placing the flask in a bath with partially frozen dichloroethane (M.p. -45 °C). CuCN (0.45 g, 5.0 mmol, 7 mol%; Aldrich) was added to the flask via syringe as a slurry in dry THF. The resulting mixture was stirred for 1 hr at -30 °C, then (5}-(+)-glycidyl tosylate (15.5 g, 68 mmol, Aldrich) dissolved in 10 mL of dry THF was added to the solution (addition time 30 minutes, reaction mixture temperature was maintained between -22 and -29 °C). The reaction was left stirring at -31 °C for 2 hr, then the DCE bath was replaced with a partially frozen o-xylene bath. Over the next 3 hours the temperature was allowed to reach -18 8C. HPLC analysis of the quenched aliquot showed complete disappearance of glycidyl tosylate.
To the cold reaction mixture, 100 mL of aq. NH4C1 solution (prepared by 1:1 dilution of the saturated solution with water) was added. The phases were separated. The

aqueous layer was extracted with 50 rnL of MTBE. Combined organic solutions were "washed with 30 mL of brine.
Closure to the epoxide. To the solution of the intermediate hydroxytosylate was added aq. solution of NaOH prepared by mixing 20 ml of 10 M stock solution (200 mmol) with 30 mL of water. The resulting bi-phasic mixture was stirred rapidly with a magnetic stirrer so that the mixture was broken into fine emulsion. After 18 hr at room temp, (checked by HPLC) the mixture was transferred to a separatory funnel and the phases were separated. The aqueous phase was extracted with 100 mL of MTBE, combined organic solutions were washed with brine and dried with MgSO*. After filtration through a paper filter, light-yellow solution was evaporated in vacuum to give a mixture the epoxide and des-bromo-arene as a light-yellow oil which solidified upon cooling to room temp. Weight 23.06 g. The mixture was used in the subsequent step without purification.
Example 4
24'-3-{5-Fluoro-3-(2,6-dichlorophenyI)-2-methoxyphenyl]-l-A'-phthalimidopropan-2-ol

(Figure Removed)
The epoxide (22.6 g of the crude mixture from the previous step, ca. 67 mraol), phthalimide (10.3 g, 70 mmol) and its potassium gait (12.9 g, 70 mmol) were placed in a 250 round-bottom flask equipped with a magnetic stirrer, a nitrogen inlet, and a temperature probe. Dry DMF (100 mL) was added to the mixture. The reaction flask was briefly purged with nitrogen and then was being heated at 75 °C with stirring for 20 hr (the progress was monitored by HPLC). Once no startihg epoxide was detected, the mixture was allowed to cool to room temp, and then mixed with 200 mL of ice-water slush. The product was extracted with MTBE (2 x 100 mL), the organic solution was washed with solution prepared from 2 parts of 1 M aq. NaOH, 1 parts brine, and 5 parts water (2 x 100 mL), then with brine until neutral pH. The resulting organic solution was dried with MgS04, filtered through a paper filter and evaporated in vacuum. The product started to

crystallize during the evaporation. The volume of the solvent was reduced to ca. 40 mL, then the residue was triturated with 200 mL of hexanes. The white solid was filtered, washed with hexanes and dried in air. Yield 23.25 g (74% over 3 steps, based on the amount of glyeidyl tosylate). M.p. 165-168 °C. JH NMR (300 MHz, CDC13) 6: 7.86 (m, 2H), 7.72 (m, 2H), 7.43 (m, 1H), 7.41 (m, 1H), 7.27 (m, 1H), 7.08 (dd, J = 3.0, 8.8 Hz, IH), 6.79 (dd, J= 3.0 Hz, 8.1 Hz, 1H), 4.23 (d5, J= 3.3,4.3,5.7, 7.9,8.5 Hz, 1H), 3.85 (dd,7=3.3,14.1 Hz, 1H), 3.80(dd,J= 8.5,14.1 Hz, 1H), 3.42 (s,3H), 2.96 (dd,J= 4.3, 13.9 Hz, 1H), 2.92 (dd, /« 7.9,13.9 Hz, 1H), 2.80 (d, /= 5.7 Hz, 1H). ES MS, m/z: 474 (M+H)*, C12 isotope pattern. Analytical purity: 97% (HPLC area% at 215 nm).
Example 5
2S'-3-[S-Fluoro-3-(2,6-dichlorophenyI)-2-methoxypbenyl]-l-A'-phtha!imidopropan-2-yl raetbanesulfonate
(Figure Removed) In a 500 mL Erlenmeyer flask equipped with a magnetic stirrer, temperature probe and an addition funnel was placed the product of Example 4 (22.0 g, 46.4 mmol), CHjClj (200 mL) and triethylamine (9.7 mL, 70 mmol). Into the addition funnel was placed CHzCb (20 mL) and methanesulfonyl chloride (5.4 mL, 70 mL). The solution of MsCl was added dropwise (addition time 10 minutes) to the stirred solution in the flask. The reaction mixture was allowed to stir at room temp, for 2 hr (checked by HPLC). White solid separated from the solution over that time.
Water (100 mL) was added to the reaction mixture while stirring it rapidly. About 120 mL of DCM was distilled off on a rotary evaporator. The residue was triturated with 200 mL of hexanes. The solid was filtered and washed excessively with water and hexanes. The cake was dried on the filter for 1 hr then overnight in a vacuum desiccator over CaSO4. Yield 25.2 g (98%) as a white fluffy crystals. M.p. >200 °C (decomp.) 'H NMR (300 MHz, CDC13) 6: 7.86 (m, 2H), 7.72 (m, 2H), 7.43 (m, 2H), 7.29 (m, 1H), 7.09 (dd, J = 3.1,8.5 Hz, 1H), 6.82 (dd, J*3.1,8.3 Hz, 1H), 5.28 (m, IH), 4.09 (dd, J = 8.6, 14.6 Hz, IH), 3.90 (dd, J = 3.3, 14.6 Hz, IH), 3.45 (s, 3H), 3.18 (dd, J = 5.4, 14.0 Hz,

1H), 3.09 (dd, J = 7.8, 14.0 Hz, 1H), 2.65 (s, 3H). !3C NMR (100 MHz, dmso-